An exploratory dose-escalating study investigating the safety,tolerability,pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

Abstract

Keywords

APRIL atacicept biological agents BLyS systemic lupus erythematosus TACI-Ig

Atacicept, a recombinant fusion protein containing the extracellular, ligand-binding portion of the transmembrane activator and calcium modulator and cyclophilin-ligand interactor receptor, and the Fc portion of human immunoglobulin (Ig) G, is designed to block the activity of B-lymphocyte stimulator and a proliferation-inducing ligand, and may have utility as a treatment for B-cell-mediated diseases, such as systemic lupus erythematosus (SLE). This Phase Ib study investigated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of intravenous (i.v.) atacicept in patients with mild-to-moderate SLE. Patients (n = 24) were randomised (5:1) to receive atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 × 9 mg/kg) or matching placebo. Patients were followed for 6 weeks after dosing (9 weeks in the 2 × 9 mg/kg cohort). Local tolerability of atacicept was comparable with that of placebo, with only mild injection-site reactions reported with atacicept. Atacicept i.v. was generally well tolerated, both systemically and locally, in patients with mild-to-moderate SLE. Atacicept displayed non-linear PK, which was predictable across doses and between single and repeat doses. The biological activity of atacicept was demonstrated by its marked effect in reducing B-cells and Ig levels in patients with SLE. This supports the utility of this therapeutic approach in the treatment of autoimmune diseases, such as SLE.

References

1 Petri M . Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7: 395–401.

2 Worrall JG Snaith ML Batchelor JR Isenberg DA . SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med 1990; 74: 319–330.

3 Isenberg D Rahman A . Systemic lupus erythematosus—2005 annus mirabilis? Nat Clin Pract Rheumatol 2006; 2: 145–152.

4 Moses N Wiggers J Nicholas C Cockburn J . Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005; 57: 30–38.

5 Kyttaris VC Katsiari CG Juang YT Tsokos GC . New insights into the pathogenesis of systemic lupus erythematosus. Curr Rheumatol Rep 2005; 7: 469–475.

6 Manson JJ Isenberg DA . The pathogenesis of systemic lupus erythematosus. Neth J Med 2003; 61: 343–346.

7 Childs SG . The pathogenesis of systemic lupus erythematosus. Orthop Nurs 2006; 25: 140–145.

8 Mok CC . Emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2006; 11: 597–608.

9 Eisenberg R Albert D . B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2: 20–27.

10.

10 Looney RJ Anolik J Sanz I . New therapies for systemic lupus erythematosus: cellular targets. Rheum Dis Clin North Am 2006; 32: 201–215.

11.

11 Goldblatt F Isenberg DA . New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005; 140: 205–212.

12.

12 Sabahi R Anolik JH . B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66: 1933–1948.

13.

13 Dorner T . Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 2006; 77: 3–11.

14.

14 Pugh-Bernard AE Cambier JC . B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18: 4510–4515.

15.

15 Dillon SR Gross JA Ansell SM Novak AJ . An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235–246.

16.

16 Moore PA Belvedere O Orr A . BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260–263.

17.

17 Schneider P MacKay F Steiner V . BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747–1756.

18.

18 Gross JA Johnston J Mudri S . TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995–999.

19.

19 Mackay F Woodcock SA Lawton P . Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697–1710.

20.

20 Zhang J Roschke V Baker KP . Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6–10.

21.

21 Cheema GS Roschke V Hilbert DM Stohl W . Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313–1319.

22.

22 Roschke V Sosnovtseva S Ward CD . BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314–4321.

23.

23 Tan SM Xu D Roschke V . Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982–992.

24.

24 Groom J Kalled SL Cutler AH . Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59–68.

25.

25 Marsters SA Yan M Pitti RM Haas PE Dixit VM Ashkenazi A . Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785–788.

26.

26 Bossen C Schneider P . BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 2006; 18: 263–275.

27.

27 Thompson JS Bixler SA Qian F . BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108–2111.

28.

28 Hendriks J Planelles L de Jong-Odding J . Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005; 12: 637–648.

29.

29 Ingold K Zumsteg A Tardivel A . Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201: 1375–1383.

30.

30 Gross JA Dillon SR Mudri S . TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289–302.

31.

31 Munafo A Priestley A Nestorov I Visich J Rogge M . Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007; 63: 647–656.

32.

32 Tak PP Thurlings RM Rossier C . Atacicept in patients with rheumatoid arthritis: results of a multicenter, Phase Ib double-blind, placebo-controlled, dose-escalating, single- and repeat-dose study. Arthritis Rheum 2008; 58: 61–72.

33.

33 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

34.

34 Bombardier C Gladman DD Urowitz MB Caron D Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

35.

35 Dall’Era M Chakravarty E Wallace D . Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142–4150.

36.

36 Eisenberg R . Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets 2006; 6: 345–350.

37.

37 Dorner T Kaufmann J Wegener WA Teoh N Goldenberg DM Burmester GR . Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.

38.

38 Ding C Jones G . Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006; 7: 464–472.